Home / Themes / AI '25: Healthcare Applications

AI '25: Healthcare Applications

Last updated

Theme thesis · 1 upload · 5/5 sections · Tickers 3 with notes · 4 pending

Loading…

Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).

Bull / Bear Details

AI in healthcare applications is compelling, driven by agentic AI and proprietary data. Despite regulatory and adoption hurdles, the potential for significant R

Thesis

AI in healthcare applications is compelling, driven by agentic AI and proprietary data. Despite regulatory and adoption hurdles, the potential for significant ROI through workflow automation and improved outcomes makes the bull case more persuasive.

Bull case

  • Proprietary healthcare datasets provide a significant and defensible competitive advantage, enabling specialized AI models to deliver superior, inaccessible insights compared to general-purpose models, thereby driving value and creating strong moats for companies leveraging this data.

  • The transition to agentic AI, capable of autonomous task completion and seamless integration into existing healthcare workflows, is poised to unlock substantial operational efficiencies, enhance decision-making, and generate tangible return on investment across the healthcare ecosystem.

  • Declining AI inference costs and the increasing viability of hybrid deployment models (training in the cloud, running on-premise) are making AI applications more economically feasible and scalable for healthcare organizations, accelerating broader adoption and implementation.

Bear case

  • Slow adoption rates due to deeply entrenched human behaviors, user mistrust, and complex organizational processes within healthcare pose a significant bottleneck, as the pace of human and procedural change lags behind rapid AI advancements.

  • The highly regulated nature of the healthcare industry, coupled with critical ethical considerations, data privacy concerns (e.g., HIPAA), and liability issues surrounding autonomous AI decision-making, creates substantial regulatory hurdles and compliance challenges that could impede widespread deployment and innovation.

  • Demonstrating clear, quantifiable, and immediate return on investment (ROI) for AI applications in healthcare remains a challenge, potentially leading to a 'mini-trough of disillusionment' if the perceived benefits do not quickly outweigh significant implementation costs and complexities.

LLM_Approved · Updated 2026-03-23

Overview

Hiring Trend Watchpoints

High-performing operators in AI '25: Healthcare Applications are actively seeking specialized talent across several key areas. Expect to see increased hiring for roles such as Healthcare AI Engineer, Medical Data Scientist (with clinical data expertise), Healthcare AI Prompt Engineer, Healthcare AI Project Manager, Healthcare AI Ethics, Governance, and Compliance Specialists, and MLOps Engineers focused on healthcare data. There is a strong demand for AI Product Managers, particularly those with experience in generative and agentic AI platforms for healthcare, and AI Solutions Technical Product Managers who can navigate regulated environments. Required skills extend beyond core AI/ML proficiency to include strong programming (Python, C/C++, Java), deep learning, natural language processing, robust data management (SQL, Power BI), cloud architecture, and application deployment. Crucially, domain-specific healthcare knowledge is paramount, even for technical roles, to ensure solutions align with clinical needs and regulatory requirements. The market is shifting away from pure research roles towards those that can deploy and maintain AI models in production, with growing interest in hybrid roles that bridge product and user experience. MLOps talent is in high demand globally, particularly in North America, Europe (Germany, UK), and Asia-Pacific (India, China), to operationalize AI at scale. Organizations are prioritizing digital fluency and AI readiness across all levels, including entry-level roles, and investing in upskilling existing staff. **Confirming Theme Execution:** Look for a sustained increase in job postings for specialized AI healthcare roles, especially those emphasizing integration, deployment, and measurable ROI. Monitor for significant internal team expansions in AI application development within major healthcare providers and payers (e.g., ELV, UNH, COR). Observe a rise in partnerships between healthtech companies and AI solution providers that include joint hiring initiatives or dedicated AI integration teams. Increased investment in AI literacy programs and certifications for existing clinical and administrative staff would also confirm theme strengthening. **Warning of Deterioration:** A noticeable decline in specialized AI healthcare job postings, particularly for application-focused and MLOps roles. A shift back towards generic AI research without clear healthcare application. Reports of significant layoffs or hiring freezes within AI departments of leading healthcare organizations or healthtech startups. A lack of emphasis on domain-specific healthcare knowledge in job descriptions for AI roles could indicate a weakening of the theme.

Forum Watchlist

Monitoring key online communities and industry forums provides critical insights into the real-world adoption, challenges, and sentiment surrounding AI in healthcare. * **HIMSS Global Health Conference & Exhibition (AI in Healthcare Forum):** This major industry event offers high-level strategic insights and showcases real-world implementations. Monitor for discussions emphasizing measurable value and ROI from AI solutions, successful case studies demonstrating improved clinical workflows and financial sustainability, and announcements of new industry standards or widespread adoption strategies. Conversely, persistent discussions about outdated systems, lack of clear guidelines, or significant barriers to adoption without clear solutions would signal weakening. * **Clinicians' Forum on AI in Health & Medicine (National Academy of Medicine - NAM):** This forum provides the perspective of medical professionals, focusing on practical application, ethical considerations, and workforce impact. Look for positive feedback on AI tools enhancing clinical decision-making and reducing burden, increased collaboration between clinicians and developers, and the development of effective training curricula. Concerns about trust in technology, potential impact on clinician roles, or unresolved ethical dilemmas would indicate weakening. * **Reddit Communities (e.g., r/AI_Agents, r/OpenAI, r/OutsourceDevHub, r/AppBuilding):** These subreddits offer a ground-level view from developers and entrepreneurs. Monitor for discussions on successful architectural patterns for PHI isolation, solutions for memory scrubbing/consent revocation, and the emergence of clear liability frameworks for autonomous agents in healthtech. Continued frustration with HIPAA compliance, security concerns, or skepticism about the true 'agentic' nature of current implementations (e.g., 'dressed-up RPA') would suggest weakening. * **HealthDevHub / clinicians.dev / Digital Health Innovation Hubs (e.g., MIT, UW):** These communities focus on the technical backbone of digital health, interoperability standards (like FHIR), and patient-centered AI solutions. Signals of strengthening include active discussions and solutions for FHIR integration, successful implementation of interoperable AI solutions, and strong collaboration between clinicians and developers. Persistent challenges with data fragmentation or difficulty translating technical solutions into practical clinical impact would indicate weakening. * **DIA's AI in Healthcare Community:** This community focuses on the broader ecosystem, including regulatory aspects, ethical considerations, and human-centric AI. Look for progress in establishing clear regulatory frameworks, successful mitigation of data bias, increased public trust in AI, and evidence of effective cross-sector collaboration. Continued fragmentation of the regulatory landscape, persistent data bias issues, or low public trust would signal weakening.

Second Order Trends

The AI '25: Healthcare Applications theme is evolving rapidly, with several second-order trends emerging beyond the foundational infrastructure build-out: 1. **AI as an Enabler for Value-Based Care and Operational Efficiency:** The narrative is shifting from AI's raw capabilities to its tangible impact on patient outcomes and cost savings within value-based care models. This includes the widespread adoption of AI for administrative burden reduction (e.g., scheduling, billing, clinical documentation), predictive analytics for proactive patient care, and workflow optimization to combat clinician burnout. Companies demonstrating clear ROI in these areas will lead. 2. **Rise of Multi-Agent and Hybrid AI Architectures:** The focus is moving beyond single-task AI to integrated multi-agent systems that autonomously coordinate complex workflows across different healthcare functions (e.g., patient support, employee management, billing, triage). Concurrently, the 'train in the cloud, run in the rack' hybrid deployment model is gaining traction to optimize cost and performance, especially for inference. 3. **Intensified Focus on AI Governance, Ethics, and Explainability (XAI):** As AI permeates critical healthcare applications, paramount concerns include data bias, patient privacy (HIPAA, GDPR), liability for AI errors, and the imperative for transparent, explainable AI models. This is driving demand for AI ethics and compliance specialists and the development of regulatory sandboxes to balance innovation with patient safety and trust. 4. **Expansion of Digital Health Ecosystem with AI-Powered Connected Care:** The 'Hospital at Home' movement and continuous patient monitoring via the Internet of Medical Things (IoMT) are becoming standard. AI acts as the intelligent layer, filtering vast datasets, providing real-time alerts, and enabling personalized, proactive care. This trend necessitates robust digital health infrastructure and seamless interoperability. 5. **AI for Accelerated Drug Discovery and Precision Medicine:** AI is increasingly leveraged in pharmaceutical R&D for drug discovery, clinical trial optimization, and developing highly personalized treatment plans based on genetic and individual patient data. This signifies a shift towards a preventative, data-driven disease management model. These trends highlight a maturing AI landscape in healthcare, moving from theoretical potential to practical, integrated, and ethically governed applications that deliver tangible benefits across the entire healthcare value chain.

Search Keywords Now

High-priority keywords and phrases to monitor for early inflection signals in AI '25: Healthcare Applications include: * **Company-Specific:** ELV AI, UNH AI, COR AI, TOI AI, FICO healthcare AI, Dell healthcare AI solutions, Nvidia healthcare partnerships, Anthropic medical agents, OpenAI healthcare applications. * **Technology & Product Terms:** Agentic AI healthcare, multi-agent systems medicine, AI workflow automation healthcare, clinical AI agents, generative AI for EHR, AI for revenue cycle management, AI for clinical decision support, hybrid AI healthcare deployment, on-premise AI medical, edge AI health devices, Model Context Protocol (MCP) healthcare adoption. * **Regulatory & Ethical Terms:** AI ethics in healthcare, HIPAA AI compliance, FDA AI medical devices, EU AI Act healthcare, AI data privacy medicine, explainable AI (XAI) healthcare, AI liability medical. * **Application & Impact Terms:** Value-based care AI, AI for clinician burnout, AI for administrative burden reduction, digital twins healthcare, AI drug discovery progress, personalized medicine AI, IoMT AI health, connected care platforms AI, healthcare data interoperability AI, AI in clinical trials. * **Market & Adoption Signals:** Healthcare AI ROI, AI healthcare adoption rates 2026, healthtech AI investment trends, AI healthcare case studies, digital health innovation trends, AI in medicine challenges, AI in healthcare workforce impact.

LLM_Approved · Updated 2026-03-23

Key Metrics3 rows
MetricCadenceWhat It SignalsUpdate Source
Global AI in Healthcare Market Size (USD Billions)AnnuallyAccelerating growth in market size indicates increasing investment and commercialization of AI applications in healthcare, supporting a bullish view. Slowdown may signal market saturation or reduced investment.LLM_Approved
Percentage of Healthcare Organizations/Professionals Actively Using AIAnnually/Bi-annuallyIncreasing adoption rates demonstrate the growing integration and acceptance of AI in healthcare workflows, indicating a bullish trend for the theme. Stagnation could signal barriers to wider implementation.LLM_Approved
Cumulative Number of FDA-Authorized AI/ML-Enabled Medical DevicesQuarterly/AnnuallyA rising number signifies successful development and regulatory approval of tangible AI applications in healthcare, indicating a bullish outlook for real-world deployment and impact. A slowdown could suggest regulatory hurdles or a decrease in new innovations.LLM_Approved

Grand View Research, Future Market Insights, Deloitte · Updated 2026-03-23

Upcoming Catalysts19 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource TypeCatalyst Source
GH_eb277c45mid-20262026-05-012026-06-30NovaSeq X transition for Guardant360 liquid tests; cost per test expected to drop and gross margins to improve toward the low-to-mid 70% range.Margin improvement and cost efficiency could meaningfully enhance profitability and free cash flow in 2026 and beyond.Ticker2026-02-19earnings_transcriptGH (ticker)
GH_551c816din 20262026-01-012026-12-31Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year.Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat.Ticker2026-02-19earnings_transcriptGH (ticker)
GH_a329742apending FDA approval; timing to be determined (2026 or later)2026-01-012027-12-31Guardant360 Liquid CDx launch following FDA approval.Adds a concurrent CDx option, potentially expanding addressable market and cross-sell; regulatory milestone risk.Ticker2026-02-19earnings_transcriptGH (ticker)
GH_17aaaaccnear term (2026)2026-01-012026-12-31ACS guideline inclusion for Shield; near-term potential to expand payer coverage and physician adoption.Could drive Shield volumes and broaden market access, supporting volume growth.Ticker2026-02-19earnings_transcriptGH (ticker)
TEM_cfd0d81cunlikely to have much of a '26 impact from ASP, but as we get into '27, we'll start to contribute2026-01-012026-12-31FDA approval of Tempus's xF liquid biopsy assay, which has been submitted to the FDA.FDA approval is a prerequisite for ADLT status and broader reimbursement, expected to significantly increase ASPs and contribute to revenue starting in 2027. Bullish if approved, bearish if rejected or delayed.Ticker2026-02-24earnings_transcriptTEM (ticker)
TEM_30f7dd10by the end of 2026 to be exiting with the vast majority of volume on that FDA-approved version2026-01-012026-12-31Completion of the migration of Tempus's xT CDx testing volume to the FDA-approved version.This migration is the biggest driver of the expected $500+ ASP upside, directly impacting gross margins and revenue per test. Bullish if completed as planned, bearish if delayed.Ticker2026-02-24earnings_transcriptTEM (ticker)
TEM_05709effover time2026-01-012028-12-31Broad unblocking of Tempus's MRD sales force and securing widespread reimbursement for MRD testing.This would significantly increase MRD test volumes, contributing to the company's 25%+ long-term growth target and market share gains in oncology diagnostics. Bullish if unblocked and reimbursed, bearish if delayed.Ticker2026-02-24earnings_transcriptTEM (ticker)
TEM_a4910b39goes live this year2026-01-012026-12-31Launch of Tempus's whole genome heme offering.This expands Tempus's diagnostic portfolio, potentially attracting new customers and increasing revenue from the heme oncology market. Bullish if launched successfully and gains traction.Ticker2026-02-24earnings_transcriptTEM (ticker)
TOI_1f5eda90In 20262026-01-012026-12-31TOI targets free cash flow positive in 2026 as it scales operations and benefits from AI-enabled efficiencies and growing capitated revenue.Key cash-flow milestone potentially enabling debt reduction, reinvestment, and valuation upgrade.Ticker2025-11-13earnings_transcriptTOI (ticker)
TOI_8d2c1227full year positive adjusted EBITDA in 20262026-01-012026-12-31Achievement of full year positive adjusted EBITDA for 2026.This is a key financial milestone indicating sustainable profitability and will significantly impact investor sentiment and valuation.Ticker2026-03-12earnings_transcriptTOI (ticker)
TOI_06d1356fcontinue expansion across the state in 2026, which would more than double the current partnership.2026-01-012026-12-31Expansion of the delegated capitation partnership with Elevance in Florida, aiming to more than double the current partnership in 2026.This expansion is a significant driver of capitated revenue growth and validates the success of TOI's delegated model, impacting top-line growth and market penetration.Ticker2026-03-12earnings_transcriptTOI (ticker)
TOI_5704e912over 80% growth in capitated revenue for the year2026-01-012026-12-31Achieving over 80% growth in capitated revenue for the full year 2026.This is a core growth driver for TOI's value-based care model, directly impacting revenue, profitability, and investor confidence in the company's strategic direction.Ticker2026-03-12earnings_transcriptTOI (ticker)
TOI_d7b60b8alaunch a proprietary new network portal in Q22026-04-012026-06-30Launch of a proprietary new network portal in Q2 2026.This portal is expected to improve provider engagement, utilization management, formulary adherence, and drive ancillary services engagement, potentially improving MLR and incremental growth.Ticker2026-03-12earnings_transcriptTOI (ticker)
TOI_0aa47467For full year 20262026-01-012026-12-31Achievement of full year 2026 financial guidance: revenue ($630M-$650M), capitated revenue (~$150M), gross profit ($97M-$107M), and adjusted EBITDA ($0M-$9M).Meeting or exceeding this guidance is crucial for investor confidence, validating the company's growth strategy and path to profitability, directly impacting valuation.Ticker2026-03-12earnings_transcriptTOI (ticker)
TOI_4b0698ebin 20262026-01-012026-12-31Realization of approximately $2 million in SG&A savings from AI-related efficiencies across prior authorization, call center, and RCM in 2026.Achieving these savings demonstrates the successful implementation and scaling of AI, contributing to margin expansion and operational leverage, which is a key bull point for the company.Ticker2026-03-12earnings_transcriptTOI (ticker)
GH_4e822abd2026–2027 timeframe2026-07-012027-12-31AstraZeneca SERENA-6 trial results; potential to drive ESR1 monitoring adoption and Guardant360 volumes if positive.Positive SERENA-6 results could accelerate therapy-monitoring use and overall Guardant360 demand; risk to sentiment if results are negative.Ticker2026-02-19earnings_transcriptGH (ticker)
TEM_0bbe29e3at some point, we'll have a really nice assay market2026-07-012027-12-31Launch of Tempus's second-generation tumor-naive MRD assay.This new assay aims to offer improved performance and compete more effectively in subtypes where tissue is sparse, potentially expanding market reach and driving volume. Bullish if launched with strong performance, bearish if further delays or poor performance.Ticker2026-02-24earnings_transcriptTEM (ticker)
TOI_a9d546ccExiting and second half of the year [2026]2026-07-012026-12-31Achieving free cash flow positivity by the end of 2026.This is a critical financial milestone demonstrating the company's ability to generate cash from operations, reducing reliance on external financing and significantly boosting investor confidence.Ticker2026-03-12earnings_transcriptTOI (ticker)
TEM_b3d020d3as we get into '27, we'll start to contribute2026-10-012027-03-31CMS granting of Advanced Diagnostic Laboratory Test (ADLT) status for Tempus's xF liquid biopsy assay.ADLT status is crucial for securing favorable and consistent reimbursement, leading to a significant ASP lift and closing the reimbursement gap with competitors. Bullish if granted, bearish if delayed or denied.Ticker2026-02-24earnings_transcriptTEM (ticker)

LLM_Approved · Updated 2026-03-20

NotesTable

Transcript Summary

DateTypeCommentDetailSentimentTickersIS CHANGE
2026-03-23group_thesisThe transcript signals AI's shift to Phase 2, emphasizing healthcare applications leveraging proprietary data for defensible moats. Companies like ELV, UNH, COR, and TOI are highlighted as beneficiaries. The focus is on agentic AI embedding into existing workflows, driving tangible ROI through effective data, design, distribution, and hybrid deployment strategies, moving beyond mere compute power.

Transcript Summary

BullishELV, UNH, COR, TOIFalse

LLM_Approved · Updated 2026-03-23

Constituents

  • GHT2
    — Guardant Health, Inc.
  • TEMT2
    — Tempus AI, Inc.
  • TOIT2
    — The Oncology Institute, Inc.
  • IQVT2
    · no notes yet
  • UNHT2
    · no notes yet
  • CORT3
    · no notes yet
  • VEEVT3
    · no notes yet